On November 21, 2022 PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, reported two executives will be giving presentations at the World Vaccine & Immunotherapy Congress, which will take place from November 28 through December 1, 2022, in San Diego (Press release, PDS Biotechnology, NOV 21, 2022, View Source [SID1234624280]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Development of a universal flu vaccine based on the InfectimuneTM platform
More than 800 attendees are expected to attend the World Vaccine & Immunotherapy Congress to examine challenges around scientific, commercial, public health and policy issues in manufacturing, clinical trials, regulation, immune profiling, biomarkers, platform technologies, and additional topics.
"We welcome the opportunity to highlight the Versamune and Infectimune platforms and their potential to address significant unmet medical needs to the biotechnology and scientific community," said Dr. Frank Bedu-Addo, PDS Biotech President and CEO. "We are looking forward to advancing our product development in both oncology and infectious disease, ultimately to improve patient care."
About Versamune
Current immunotherapies have demonstrated an ability to treat certain cancers, but limitations with their effectiveness persist. Versamune is a novel investigational T cell activating platform designed to stimulate a precise immune system response to cancer-specific proteins. PDS Biotech is advancing multiple Versamune based clinical and pre-clinical programs with its lead clinical candidate – PDS0101 – targeting HPV-positive cancers.
About InfectimuneTM
Infectimune is a novel proprietary investigational T cell immune activating platform technology designed to train the immune system to better protect against disease. The Infectimune platform stimulates the immune system to recognize the pathogen and induce potent killer T cell and memory T cell response for long-term protection safely with no clinically relevant toxicities.